1. Introduction {#s0005}
===============

Identification of unintended effects of drug therapy is an essential part of post-marketing drug surveillance (pharmacovigilance), as knowledge of rare side-effects is limited at the time of marketing of new medications ([@bb0115]). Unintended effects of drugs may involve an increase or a reduction in cancer risk ([@bb0065], [@bb0135]). Although systematic and comprehensive testing of genotoxicity and carcinogenicity is performed for any new drug prior to marketing ([@bb0005]), both these laboratory assays and the premarketing phase-3 trials are disadvantaged by the typically long latency period of cancer development in humans ([@bb0135], [@bb0010]). For example, the excess risk of breast cancer induced by use of menopausal or contraceptive hormone therapy first becomes apparent after 5--10 years of continued use ([@bb0055], [@bb0145]), and the protective effect of aspirin against colorectal cancer requires at least five years of regular use ([@bb0015], [@bb0030]). Traditional approaches in pharmacovigilance (based primarily on spontaneous reporting of adverse events) rarely detect drug--cancer associations, primarily due to the long induction time of most cancer types, which separate the use of the drug from the diagnosis by several years. As most individual cancer types are rare and have a long latency, pre-marketing clinical trials are unlikely to detect carcinogenic or chemopreventive effects of drugs due to the typically small size and short follow-up of these trials. Since neither spontaneous reporting nor clinical trials would be effective in capturing signals, the primary tool in surveillance of drugs for unintended carcinogenic or cancer preventive effects would be analyses of large administrative databases. Such studies have been instrumental in the identification of carcinogenic effects of several drugs, e.g., female hormone therapy and phenacetin ([@bb0065]).

Denmark has a long history of establishing nationwide health care registries and databases with information on all Danish residents ([@bb0120]). Two of the nationwide registries with the highest data quality, the Danish Prescription Registry (initiated in 1995 ([@bb0075])) and the Danish Cancer Registry (established in 1943 ([@bb0050])), hold virtually complete data on drug prescriptions and incident cancer cases and thus provide a unique setting for active surveillance of cancer risk associated with the use of prescription drugs.

We established a system to screen for associations between prescription drug use and cancer risk, based on a multiple case--control design. In the present paper, we describe (i) the source population and data sources, (ii) the initial screening process, (iii) the strategy for internal validation of signals, and (iv) initial results from the nationwide screening.

2. Setting and Data Sources {#s0010}
===========================

2.1. Data Sources {#s0015}
-----------------

The entire Danish population is provided free tax-supported medical care by the National Health Service ([@bb0120]). For administration and maintenance of this health care system, numerous administrative and health registries have been established. In addition to supporting high quality service in the health care system, these registries allow population-based studies covering all residents in Denmark (approximately 5.6 millions).

The main data sources for our screening system include the Danish Cancer Registry ([@bb0050]), the Danish Prescription Registry ([@bb0075]), the Danish National Patient Registry ([@bb0080]), and the Danish Civil Registration System ([@bb0090]).

The Danish Cancer Registry ([@bb0050]) has recorded incident cancer cases on a nationwide basis since 1943 and has been shown to have accurate and almost complete ascertainment of cases ([@bb0050], [@bb0110]). Approximately 90% of cancer cases in the registry are histologically verified, while the remaining are mainly represented by brain tumours and cancers in very old and/or frail patients. Cancer diagnoses are recorded using the International Classification of Diseases, version 10 (ICD-10), and the ICD for Oncology (ICD-O-3).

The Danish National Prescription Registry ([@bb0075]) contains data on all prescription drugs dispensed to Danish residents since 1995. The data include the type of drug, date of dispensing, and quantity dispensed. Drugs are categorized according to the Anatomical Therapeutic Chemical (ATC) index, a hierarchical classification system developed by the WHO ([@bb0140]).

The Danish National Patient Register ([@bb0080]) contains nationwide data on all non-psychiatric hospital admissions since 1977 and all outpatient specialist contacts in hospital setting since 1995. Discharge/contact diagnoses are coded using ICD-8 (1977--1993) and ICD-10 (1994--).

The Danish Civil Registration System ([@bb0090]) contains data on vital status (date of death) and migration to and from Denmark, allowing sampling of general population controls and complete tracking of study subjects.

2.2. Data Linkages {#s0020}
------------------

Data sources were linked by the civil registry number, a unique identifier assigned to all Danish residents since 1968 ([@bb0090]). Linkage was performed within Statistics Denmark, a governmental institution that collects and maintains electronic records for a broad spectrum of statistical and scientific purposes ([@bb0125]).

2.3. Identification of Cancer Cases {#s0025}
-----------------------------------

From the Danish Cancer Registry, we identified all individuals in Denmark with incident cancers diagnosed between January 1, 2000 and December 31, 2012. We defined the index date as the date of diagnosis. Cases were restricted to histologically verified cancers (except for tumours of the central nervous system, of which some are based on clinical and imaging findings only, and haematological malignancies).

Exclusion criteria were age outside 18--85 years at index date and migration to or from Denmark anytime during the 10 years prior to index date. This ensured at least 10 years of complete follow-up prior to sampling for all study subjects and a minimum of five years of prescription data (available from 1995). We excluded the youngest since both drug use and cancer incidence are low among children and adolescents. We further excluded individuals with a previous history of cancer (except non-melanoma skin cancer) thus focusing on primary incident cancers.

Based on ICD-O topography and morphology codes for 34 cancer sites, we restricted the cancer outcomes to 99 cancer subtypes. For a complete list of the included cancers and their definitions within the Cancer Registry, see [Appendix A](#ec1000){ref-type="supplementary-material"}.

2.4. Selection of Controls {#s0030}
--------------------------

Controls were selected using risk set sampling. For each case, we randomly selected 10 controls from all Danish citizens applying the same exclusion criteria as for cases and with the same sex and birth year as the case. Controls were assigned an index date identical to that of the corresponding case. Each subject was eligible for sampling as a control before becoming a case and could be sampled as a control more than once. Thereby, the calculated odds ratios (ORs) provide unbiased estimates of the corresponding incidence rate ratios (IRRs) that would have emerged from cohort studies conducted in the underlying source population ([@bb0105]).

2.5. Approvals and Funding {#s0035}
--------------------------

The study was approved by the Danish Data Protection Agency. According to Danish law, studies based solely on register data do not require approval from an ethics review board ([@bb0125]). The study was funded by the Danish Council for Independent Research (grant 4004-00234B). The funder had no role in the study conduct, interpretation of data, or reporting of the findings.

3. Initial Screening Process {#s0040}
============================

The process consisted of two stages. In the first stage, we identified potential signals, i.e., drug--cancer associations. Those associations meeting our strength criteria qualified for further evaluation of causation in the second stage (see "Evaluation of Signals" below).

3.1. Classification of Drug Exposures {#s0045}
-------------------------------------

For each cancer or cancer subtype in the screening process, we included all drugs and drug classes that either had 10 observed long-term users (defined as ≥ 8 prescriptions) among the cases or where 10 cases were expected to be long-term users based on drug exposure among the controls given no drug--cancer association. Single drugs were defined by the fifth level of the ATC-system (e.g., C07AB02, metoprolol), and drug classes were analysed at both the second (e.g., C07, all beta-blockers) and fourth level (e.g., C07AB, selective beta-blockers).

Exposure to a specific drug or drug class was assessed from prescription fills recorded in the Prescription Registry prior to the index date for cases and controls. We classified use as non-use (0--1 prescription), intermediate use (2--7 prescriptions), and long-term use (≥ 8 prescriptions). Eight prescriptions was chosen as a cut-off as drugs for chronic treatment are typically supplied for 3 months use for each dispensing in Denmark, whereby our definition of long-term use would correspond to two years\' cumulative treatment.

In all assessments of primary drug exposures or confounders, we disregarded prescriptions redeemed within one year prior to the index date. This was done for two reasons. First, such recent exposure is unlikely to be associated with cancer development ([@bb0065], [@bb0135]). Secondly, drug use has been shown to increase in the year prior to cancer diagnoses ([@bb0070]), likely due to treatment of early symptoms of yet undiagnosed cancers. Such treatment patterns raise the possibility of reverse causation bias ([@bb0025]).

3.2. First-level Screening {#s0050}
--------------------------

The analyses followed a conventional matched case--control approach using conditional logistic regression. We estimated odds ratios (OR) for each individual cancer outcome associated with the drug exposures by comparing long-term use (≥ 8 fills) to non-use (i.e., disregarding intermediate use). Potential confounding by gender, age, and calendar time was handled by the design (matching) and conditional analysis. We further adjusted for Charlson Comorbidity Index (CCI) score ([@bb0020], [@bb0130]) (categorized as 0, 1, 2, 3 or 4 +) using information on medical history recorded in the Patient Registry from 1977 up to one year prior to index date, and years of schooling (categorized into basic \[≤ 10 years\], short/medium \[11--13 years\], long \[14 + years\], or missing) ([@bb0035]).

All analyses were performed using Stata Release 13.0 (StataCorp, College Station, TX, USA).

3.3. Definition of Signals {#s0055}
--------------------------

Following the initial analysis, we identified all drug--cancer pairs meeting our criteria for strength of association. Signals were defined as drug--cancer associations with an OR greater than 1.5 or less than 0.67, or a lower limit of the 95% confidence interval above 1.2 or a higher limit below 0.83.

4. Evaluation of Signals {#s0060}
========================

All signals identified in the initial screening procedure were examined further according to two additional criteria: (i) specificity and (ii) dose--response relationship.

4.1. Outcome Specificity {#s0065}
------------------------

Signals were tested for specificity, i.e., whether the drug was associated with a particular cancer types or with cancer overall. No drug is known to increase the risk of all cancer types, and absence of specificity of the signals thus suggests the existence of bias, e.g., residual confounding by smoking or other factors such as surveillance. In the test for specificity of a given signal, we compared the point estimate for any drug--cancer association with the particular drug\'s association with cancer overall. To meet the criteria for specificity, we required that the ratio of the OR for the signal to the overall OR was outside the range of 0.83--1.20.

4.2. Dose--Response Pattern {#s0070}
---------------------------

We tested each signal for presence of a dose--response relationship. We first restricted the data to ever-users of the drug of interest and then estimated the incremental OR per prescription among the remaining users, while capping exposure at 50 prescriptions. This incremental OR corresponds to the slope of the dose--response curve. To evaluate whether a dose--response relationship was present, we tested the null hypothesis that the slope of the dose--response curve was zero. We arbitrarily selected a cutoff of *p* \< 0.10.

5. Results {#s0075}
==========

Following exclusions, the final study population consisted of 278,485 incident cancer cases. The most frequent cancers were ductal adenocarcinoma of the breast among females (n = 36,805), prostate adenocarcinoma among men (n = 34,443), and colon adenocarcinoma in both genders (n = 24,557). In the initial screening process, 22,125 drug--cancer pairs underwent evaluation. For the majority of cancer types (61 of 99), more than 100 drug--cancer pairs underwent evaluation.

A total of 4561 signals (i.e., drug--cancer pairs meeting criteria for strength of association) were identified in the initial screening process, most frequently for cancers of the lung (196 signals for squamous cell carcinoma, 178 for small cell carcinoma and 176 for other adenocarcinomas). For five of the 99 cancer types, we found no signals in the initial screening process ([Table 1](#t0005){ref-type="table"}).

Of the signals identified in the initial screening stage, 3464 (75.9%) failed to meet the criteria for dose--response relationship, 12 (0.2%) failed the test for outcome specificity, while 65 (1.4%) failed both criteria; thus leaving 1020 signals. The signals most commonly disqualified because of the specificity criterion were drug--cancer pairs involving squamous cell carcinoma of the pharynx and various types of lung cancer. An overview of the total number of cases, drug--cancer pairs undergoing evaluation, and final signals are displayed in [Table 1](#t0005){ref-type="table"}.

Of the final 1020 signals, 159 were observed among drug classes at the second level of the ATC-system, 351 among drug classes at the fourth level, and 510 for single agents (fifth level).

[Table 2](#t0010){ref-type="table"} displays all signals indicating a reduced cancer risk associated with long-term use of a drug class (on second ATC level), among associations based on more than 100 exposed cases or 1000 exposed controls. [Table 3](#t0015){ref-type="table"} displays signals suggesting an increased risk with a similar restriction. The full list of all 1020 signals for drug classes at the second or fourth level of the ATC-system and for single drug substances are provided in [Supplementary Results I](#ec0005){ref-type="supplementary-material"}--[II](#ec0010){ref-type="supplementary-material"}, [III](#ec0015){ref-type="supplementary-material"}--[IV](#ec0020){ref-type="supplementary-material"}, and [V](#ec0025){ref-type="supplementary-material"}--[VI](#ec0030){ref-type="supplementary-material"}, respectively.

6. Discussion {#s0080}
=============

In this large-scale nationwide screening study, we evaluated 22,125 drug--cancer pairs and identified 1020 signals (i.e., drug--cancer associations) that met the criteria for strength of association, specificity, and dose--response pattern. The majority of the identified signals (703 signals) indicated an increased cancer risk associated with the specific prescription drugs, while a smaller proportion (317 signals) were inverse associations indicative of a potential chemopreventive effect. Our findings constitute a broad basis for future comprehensive studies of signals suggesting a potential causal relationship between the specific drugs and cancer types. The public health importance of identifying carcinogenic effects of drugs is evident, since even small carcinogenic effects of widely used drugs will translate into numerous drug-induced cancer cases. Moreover, neutral associations have important value by reassuring prescribers and patients of the safety of drugs, which will promote their appropriate use. Lastly, identification of potential chemopreventive drug effects may provide a clue to development of new compounds for cancer prophylaxis and treatment.

The primary strength of our study is the use of the Danish nationwide health registries, ensuring a prescription history of up to 17 years and virtually complete ascertainment of cancer cases. The large study population also allowed evaluation of drug exposure in relation to risk of more rare cancers. The quality of the data in the Danish Prescription Registry ([@bb0075]) and the Danish Cancer Registry ([@bb0050]) has been found to be high ([@bb0075], [@bb0050], [@bb0110]). Lastly, the detailed stratification according to cancer histology avoided lumping of cancer types with markedly different histology. For example, lung cancer consists of squamous cell carcinoma, adenocarcinoma, small cell carcinoma, large cell carcinoma and carcinoids, among others. As these cancer subtypes have markedly different biology, it is unlikely that their development would be similarly affected by the same drugs.

The principal weakness of the study is the lack of adjustment for potential confounding from life-style factors. Although we adjusted for education and a measure of comorbidity, our analyses would benefit from adjustment for life-style factors, such as obesity, alcohol consumption, and smoking. However, this information is not available in the Danish health registries. Moreover, a generic confounder adjustment relevant to all cancers is difficult as no universal confounders exist, which emphasizes the need for tailored analyses of our individual signals.

Under the null hypotheses and with the traditional α of 0.05, evaluation of 22,000 associations is expected to result in approximately 1100 false positive associations. Importantly, this pertains to the initial signals (n = 4561) before dose--response and specificity requirements. One way to handle this would be to adjust for multiple testing, e.g. Bonferroni correction ([@bb0095]). Although such adjustment reduces the number of false positive associations, it also reduces the likelihood that a true association will be captured. Given the explorative nature of our screening study, we should not reject signals before they can be subjected to rigorous evaluation. Thus, we did not include any correction for multiple testing, as also recommended by others ([@bb0100]).

Some of the identified signals can be attributed to confounding by indication. This is most notable for the observed associations with lung cancers. As an example, drugs used to treat obstructive lung diseases exhibited a strong association with squamous cell carcinoma of the lung (OR, 2.61), which is likely explained by these drugs being used for chronic obstructive pulmonary disease (COPD), which is caused primarily by smoking ([Supplementary Results I](#ec0005){ref-type="supplementary-material"}). Nevertheless, our algorithm succeeded in identifying established or previously reported associations, such as the association between use of female hormone therapy and risk of ductal and lobular adenocarcinomas ([@bb0060]) (OR 1.92 and 2.65, respectively, [Supplementary Results V](#ec0025){ref-type="supplementary-material"}), and the association between the antihypertensive drug hydrochlorothiazide and lip cancer ([@bb0040]) (OR 6.93, [Supplementary Results V](#ec0025){ref-type="supplementary-material"}). Such findings provide assurance that our approach is capable of identifying true associations.

Some of the signals we have identified clearly warrant further investigation. For example, the two antibiotics pivmecillinam and sulfamethizole displayed odds ratios of about 13 and 6, respectively, for squamous cell carcinoma of the bladder ([Supplementary Results V](#ec0025){ref-type="supplementary-material"}). Both drugs are used specifically to treat urinary tract infections and, as such, this signal might reflect a carcinogenic effect of inflammation due to recurrent infections. However, as both drugs are designed to accumulate in the bladder lumen and because the signal was very strong, this signal should be considered a candidate for future studies. Such studies should be designed specifically for the individual drug--cancer association, by employing focused and comprehensive confounder adjustment and by focusing on etiologically relevant exposure windows for the specific cancer outcomes under study.

When deciding whether a given drug--cancer association is worthy of further study, i.e., prioritizing the many signals reported in this study, parameters other than the strength of the association should be considered. Thought should be given to the potential for confounding by indication or contraindication as discussed above, as well as biological plausibility, e.g., by considering the pharmacological mechanism of the drug and/or drawing upon findings in other studies, whether experimental, clinical or observational. In addition, the potential public health impact of a putative association should be considered, as reflected by the number of attributable cases, the aggressiveness of the cancer outcome and the age of those affected. Finally, several drugs evaluated by the International Agency for Research on Cancer (IARC) have been categorized as probably (Group 2 A) or possibly (Group 2B) carcinogenic to humans, because epidemiological evidence has not been definitive, or because carcinogenicity has been demonstrated only in experimental animals ([@bb0065], [@bb0045]). Additional studies and continued monitoring of the potential carcinogenicity of these drugs are of paramount importance.

Another valuable next step would be a full-scale replication of our study, a common approach in, e.g., genome-wide screening studies ([@bb0085]). This would require access to data sources comparable to the Danish registries, and should ideally hold data on potential life-style confounders or health-seeking behaviour. The combined results of the index and replication studies would help prioritize the signals that warrant further research.

In conclusion, we have presented an approach for nationwide screening of associations between the use of prescribed medications and cancer risk. The results of this screening should undergo external validation and the single drug--cancer associations should be subject to tailored analysis, in order to enhance our understanding of carcinogenic or chemopreventive effects of prescription drugs.
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Overview of cancer cases and number of signals according to the screening phases, i.e., evaluation in the first stage of the algorithm, initial screening, and the second stage, internal validation.

Table 1

  No   Cancer                                                Cancer cases   Drug--cancer pairs evaluated   Signals passed stage 1   Signals passed stage 2
  ---- ----------------------------------------------------- -------------- ------------------------------ ------------------------ ------------------------
  1    Lip (Squamous cell carcinoma)                         491            113                            19                       3
  2    Lip (Other)                                           31             0                              0                        0
  3    Oral cavity (Squamous cell carcinoma)                 3304           408                            134                      27
  4    Oral cavity (Other)                                   272            63                             19                       1
  5    Salivary glands (Adenocarcinoma)                      368            77                             15                       2
  6    Salivary glands (Other)                               180            39                             7                        0
  7    Pharynx (Squamous cell carcinoma)                     3358           376                            135                      20
  8    Pharynx (Other)                                       240            52                             24                       3
  9    Oesophagus (Squamous cell carcinoma)                  1889           296                            101                      24
  10   Oesophagus (Adenocarcinoma)                           1925           328                            79                       20
  11   Oesophagus (Other)                                    412            107                            25                       7
  12   Stomach (Adenocarcinoma)                              4775           463                            51                       11
  13   Stomach (Other)                                       412            97                             15                       2
  14   Small intestine (Adenocarcinoma)                      373            102                            13                       2
  15   Small intestine (Carcinoid)                           239            65                             20                       5
  16   Small intestine (Other)                               147            43                             18                       1
  17   Colon (Adenocarcinoma)                                24,557         809                            66                       14
  18   Colon (Carcinoid)                                     386            84                             9                        1
  19   Colon (Other)                                         283            77                             15                       4
  20   Rectum (Adenocarcinoma)                               13,445         654                            94                       21
  21   Rectum (Other)                                        249            70                             14                       1
  22   Liver (Hepatocellular carcinoma)                      1382           301                            121                      39
  23   Liver (Adenocarcinoma)                                329            94                             21                       4
  24   Liver (Bile duct carcinoma)                           231            71                             35                       5
  25   Liver (Other)                                         336            107                            44                       15
  26   Gallbladder and biliary tract (Adenocarcinoma)        1129           253                            46                       13
  27   Gallbladder and biliary tract (Bile duct carcinoma)   111            28                             8                        2
  28   Gallbladder and biliary tract (Other)                 128            49                             18                       3
  29   Pancreas (Adenocarcinoma)                             5522           500                            64                       10
  30   Pancreas (Other)                                      1245           268                            44                       13
  31   Larynx (Squamous cell carcinoma)                      2630           351                            110                      20
  32   Larynx (Other)                                        108            31                             17                       1
  33   Lung (Adenocarcinoma)                                 14,363         707                            176                      55
  34   Lung (Squamous cell carcinoma)                        8526           619                            196                      66
  35   Lung (Small cell carcinoma)                           6745           564                            178                      62
  36   Lung (Other (non-small cell))                         3829           444                            125                      31
  37   Lung (Carcinoid)                                      783            198                            66                       14
  38   Lung (Large cell carcinoma)                           840            184                            55                       9
  39   Lung (Other)                                          3609           436                            113                      30
  40   Bones, joints and cartilage (Chondrosarcoma)          211            40                             9                        4
  41   Bones, joints and cartilage (Osteosarcoma)            83             3                              0                        0
  42   Bones, joints and cartilage (Ewing sarcoma)           42             0                              0                        0
  43   Bones, joints and cartilage (Other)                   82             4                              3                        0
  44   Skin (Melanoma)                                       16,331         708                            82                       14
  45   Skin (Other)                                          49             3                              1                        0
  46   Mesothelium and connective tissue (Sarcomas)          1404           229                            28                       5
  47   Mesothelium and connective tissue (Mesothelioma)      1125           206                            38                       7
  48   Mesothelium and connective tissue (Other)             432            112                            33                       11
  49   Breast (female) (Adenocarcinoma, Ductal carcinoma)    36,805         899                            75                       11
  50   Breast (female) (Adenocarcinoma, other)               5275           525                            58                       14
  51   Breast (female) (Adenocarcinoma, Lobular carcinoma)   5514           516                            62                       20
  52   Breast (female) (Other)                               723            178                            27                       1
  53   Breast (male) (Other)                                 287            74                             16                       2
  54   Vulva and vagina (Squamous cell carcinoma)            815            205                            34                       5
  55   Vulva and vagina (Other)                              225            79                             18                       3
  56   Cervix uteri (Squamous cell carcinoma)                3208           354                            96                       23
  57   Cervix uteri (Adenocarcinoma)                         725            121                            18                       4
  58   Cervix uteri (Other)                                  391            80                             28                       2
  59   Corpus uteri (Adenocarcinoma, endometrioid)           5130           525                            161                      48
  60   Corpus uteri (Adenocarcinoma, other)                  940            208                            52                       7
  61   Corpus uteri (Sarcomas)                               574            147                            37                       8
  62   Corpus uteri (Adenocarcinoma, serous)                 420            131                            39                       7
  63   Corpus uteri (Other)                                  538            138                            42                       4
  64   Ovary (Adenocarcinoma, serous)                        3002           396                            62                       18
  65   Ovary (Adenocarcinoma, other)                         916            231                            38                       6
  66   Ovary (Adenocarcinoma, endometrioid)                  527            117                            21                       4
  67   Ovary (Adenocarcinoma, mucinous carcinoma)            482            101                            20                       5
  68   Ovary (Adenocarcinoma, clear cell)                    257            67                             15                       1
  69   Ovary (Other)                                         591            141                            32                       2
  70   Prostate (Adenocarcinoma)                             34,443         800                            126                      34
  71   Prostate (Other)                                      256            70                             16                       3
  72   Testis (Seminoma)                                     2073           134                            33                       4
  73   Testis (Teratoma)                                     586            21                             5                        1
  74   Testis (Embryonal carcinoma)                          468            17                             9                        0
  75   Testis (Choriocarcinoma)                              109            1                              0                        0
  76   Testis (Other)                                        99             1                              0                        0
  77   Kidney (Adenocarcinoma, clear cell)                   5083           496                            120                      21
  78   Kidney (Adenocarcinoma, other)                        385            105                            31                       7
  79   Kidney (Other)                                        177            48                             9                        0
  80   Renal pelvis and ureter (Urothelial carcinoma)        713            177                            35                       5
  81   Renal pelvis and ureter (Other)                       106            30                             7                        0
  82   Bladder (Urothelial carcinoma)                        7611           565                            79                       13
  83   Bladder (Adenocarcinoma)                              425            101                            27                       5
  84   Bladder (Squamous cell carcinoma)                     233            72                             22                       11
  85   Bladder (Other)                                       277            90                             20                       4
  86   Eye (Melanoma)                                        307            56                             5                        0
  87   Eye (Other)                                           50             10                             5                        1
  88   Brain and meninges (Glioma)                           3669           391                            55                       15
  89   Brain and meninges (Meningioma)                       2045           307                            51                       10
  90   Brain and meninges (Other)                            653            104                            17                       5
  91   Thyroidea (Adenocarcinoma, Papillary carcinoma)       1260           191                            56                       11
  92   Thyroidea (Follicular carcinoma)                      339            80                             32                       6
  93   Thyroidea (Other)                                     399            91                             18                       6
  94   Hodgkin (Other)                                       1346           184                            59                       8
  95   Non-Hodgkin (Other)                                   9002           607                            83                       17
  96   Multiple myeloma (Other)                              3257           412                            52                       13
  97   Leukaemia (Lymphatic)                                 3494           405                            51                       12
  98   Leukaemia (Myeloid)                                   2719           354                            55                       5
  99   Leukaemia (Other)                                     615            139                            28                       6
       TOTAL                                                 278,485        22,125                         4561                     1020

###### 

16 signals (drug--cancer associations) indicative of a decreased cancer risk associated with drug classes at second ATC-level restricted to signals with more than 100 long-term users among cancer cases or 1000 among controls for the given drug exposure.

Table 2

  Cancer                                        ATC   Drug class                                          Cases expo/nonexpo   Controls expo/nonexpo   OR (95%CI)[a](#tf0010){ref-type="table-fn"}   Spec.[b](#tf0015){ref-type="table-fn"}   *p*[⁎⁎⁎](#tf0005){ref-type="table-fn"}
  --------------------------------------------- ----- --------------------------------------------------- -------------------- ----------------------- --------------------------------------------- ---------------------------------------- ----------------------------------------
  Prostate (Adenocarcinoma)                     A06   Drugs for constipation                              63/34,062            1987/337,637            0.33 (0.26--0.43)                             0.73                                     0.01
  Pharynx (Squamous cell carcinoma)             C10   Lipid modifying agents                              238/2953             3168/28,929             0.47 (0.40--0.54)                             0.94                                     \< 0.01
  Oral cavity (Squamous cell carcinoma)         C10   Lipid modifying agents                              274/2866             3092/28,577             0.56 (0.49--0.65)                             0.94                                     0.03
  Oral cavity (Squamous cell carcinoma)         R01   Nasal preparations                                  78/3007              1244/29,426             0.58 (0.46--0.73)                             0.97                                     \< 0.01
  Lung (Other (non-small cell))                 A10   Drugs used in diabetes                              215/3571             2143/35,827             0.62 (0.53--0.72)                             0.94                                     0.04
  Lung (Adenocarcinoma)                         A10   Drugs used in diabetes                              691/13,562           7415/134,978            0.63 (0.58--0.69)                             0.94                                     0.09
  Lung (Small cell carcinoma)                   D01   Antifungals for dermatological use                  114/5849             1554/56,978             0.66 (0.54--0.80)                             0.98                                     0.05
  Larynx (Squamous cell carcinoma)              C09   Agents acting on the renin--angiotensin system      384/2117             4370/20,674             0.66 (0.58--0.75)                             1.01                                     0.06
  Pharynx (Squamous cell carcinoma)             C09   Agents acting on the renin--angiotensin system      419/2793             4572/27,633             0.67 (0.59--0.75)                             1.01                                     0.05
  Corpus uteri (Adenocarcinoma, endometrioid)   R03   Drugs for obstructive airway diseases               344/4395             4732/42,762             0.72 (0.64--0.81)                             1.16                                     \< 0.01
  Lung (Small cell carcinoma)                   A10   Drugs used in diabetes                              399/6262             3708/63,104             0.72 (0.64--0.81)                             0.94                                     0.03
  Cervix uteri (Squamous cell carcinoma)        G03   Sex hormones and modulators of the genital system   1187/1692            13,254/14,514           0.73 (0.67--0.81)                             1.12                                     \< 0.01
  Prostate (Adenocarcinoma)                     N03   Antiepileptics                                      552/33,475           7698/332,407            0.74 (0.68--0.81)                             1.01                                     \< 0.01
  Lung (Squamous cell carcinoma)                C09   Agents acting on the renin--angiotensin system      1589/6490            16,324/64,287           0.76 (0.72--0.81)                             1.01                                     0.01
  Rectum (Adenocarcinoma)                       N06   Psychoanaleptics                                    984/11,821           12,535/114,922          0.77 (0.71--0.82)                             1.01                                     \< 0.01
  Rectum (Adenocarcinoma)                       N02   Analgesics                                          1603/9929            19,197/94,719           0.78 (0.74--0.83)                             1.06                                     \< 0.01

Notes: OR = odds ratio; CI = confidence interval.

*p*-Value as obtained in the dose--response analysis.

Adjusted for gender, age, and calendar time (by design) as well as Charlson Comorbidity Index (CCI) score and educational level.

Specificity, i.e. the association (OR) between the drug and overall cancer risk.

###### 

57 signals (drug--cancer associations) indicative of an increased cancer risk associated with drug classes at second ATC-level restricted to signals with more than 100 long-term users among cancer cases or 1000 among controls for the given drug exposure.

Table 3

  Cancer                                                ATC   Drug class                                          Cases expo/nonexpo   Controls expo/nonexpo   OR (95%CI)[a](#tf0025){ref-type="table-fn"}   Spec.[b](#tf0030){ref-type="table-fn"}   *p*[⁎⁎⁎](#tf0020){ref-type="table-fn"}
  ----------------------------------------------------- ----- --------------------------------------------------- -------------------- ----------------------- --------------------------------------------- ---------------------------------------- ----------------------------------------
  Lung (Squamous cell carcinoma)                        R03   Drugs for obstructive airway diseases               1824/5947            7189/73,406             2.61 (2.45--2.78)                             1.16                                     \< 0.01
  Lung (Carcinoid)                                      R03   Drugs for obstructive airway diseases               147/563              635/6679                2.43 (1.96--3.00)                             1.16                                     0.09
  Lung (Other (non-small cell))                         R03   Drugs for obstructive airway diseases               680/2843             3194/32,806             2.08 (1.89--2.29)                             1.16                                     0.02
  Oesophagus (Adenocarcinoma)                           A02   Drugs for acid related disorders                    366/1317             1976/15,268             2.07 (1.81--2.36)                             1.07                                     \< 0.01
  Pharynx (Squamous cell carcinoma)                     N05   Psycholeptics                                       771/2129             4096/26,149             2.07 (1.89--2.28)                             1.08                                     \< 0.01
  Liver (Hepatocellular carcinoma)                      A10   Drugs used in diabetes                              301/1056             825/12,852              2.06 (1.72--2.46)                             0.94                                     0.02
  Lung (Other)                                          R03   Drugs for obstructive airway diseases               618/2685             2951/30,893             2.03 (1.83--2.24)                             1.16                                     \< 0.01
  Vulva and vagina (Squamous cell carcinoma)            D07   Corticosteroids, dermatological preparations        110/460              597/5457                1.99 (1.57--2.54)                             1.02                                     \< 0.01
  Hodgkin (Other)                                       D07   Corticosteroids, dermatological preparations        106/910              629/9999                1.93 (1.53--2.43)                             1.02                                     0.05
  Oral cavity (Squamous cell carcinoma)                 N05   Psycholeptics                                       821/2030             4663/24,948             1.91 (1.73--2.10)                             1.08                                     \< 0.01
  Lung (Squamous cell carcinoma)                        L04   Immunosuppressants                                  149/8296             588/84,152              1.87 (1.55--2.25)                             1.13                                     0.04
  Lung (Adenocarcinoma)                                 N07   Other nervous system drugs                          228/13,549           1131/139,827            1.84 (1.59--2.13)                             1.23                                     \< 0.01
  Kidney (Adenocarcinoma, clear cell)                   C09   Agents acting on the renin--angiotensin system      1287/3484            8107/40,331             1.82 (1.68--1.96)                             1.01                                     \< 0.01
  Lip (Squamous cell carcinoma)                         C03   Diuretics                                           131/316              818/3662                1.80 (1.39--2.33)                             1.05                                     \< 0.01
  Larynx (Squamous cell carcinoma)                      N05   Psycholeptics                                       610/1704             3552/20,101             1.79 (1.61--1.99)                             1.08                                     \< 0.01
  Kidney (Adenocarcinoma, clear cell)                   C03   Diuretics                                           1147/3380            7528/39,297             1.78 (1.64--1.93)                             1.05                                     0.05
  Kidney (Adenocarcinoma, clear cell)                   C08   Calcium channel blockers                            879/3878             5250/43,226             1.77 (1.63--1.93)                             1.04                                     \< 0.01
  Lung (Small cell carcinoma)                           R05   Cough and cold preparations                         486/4974             2560/53,959             1.77 (1.59--1.97)                             1.12                                     \< 0.01
  Lung (Small cell carcinoma)                           P01   Antiprotozoals                                      180/6136             889/62,483              1.69 (1.43--1.99)                             1.14                                     \< 0.01
  Larynx (Squamous cell carcinoma)                      N02   Analgesics                                          505/1695             2866/19,793             1.68 (1.49--1.89)                             1.06                                     \< 0.01
  Liver (Hepatocellular carcinoma)                      N02   Analgesics                                          359/784              1658/10,175             1.67 (1.42--1.96)                             1.06                                     \< 0.01
  Lung (Squamous cell carcinoma)                        P01   Antiprotozoals                                      229/7765             1128/79,205             1.66 (1.43--1.93)                             1.14                                     0.01
  Stomach (Adenocarcinoma)                              A02   Drugs for acid related disorders                    757/3397             4903/37,921             1.65 (1.51--1.81)                             1.07                                     \< 0.01
  Liver (Hepatocellular carcinoma)                      N05   Psycholeptics                                       373/823              2123/10,304             1.63 (1.40--1.89)                             1.08                                     \< 0.01
  Oral cavity (Squamous cell carcinoma)                 N02   Analgesics                                          677/2085             3912/24,711             1.63 (1.47--1.81)                             1.06                                     \< 0.01
  Lung (Adenocarcinoma)                                 R03   Drugs for obstructive airway diseases               2100/11,087          11,905/122,450          1.63 (1.55--1.72)                             1.16                                     \< 0.01
  Breast (female) (Adenocarcinoma, Lobular carcinoma)   G03   Sex hormones and modulators of the genital system   2251/2622            16,711/31,474           1.62 (1.52--1.72)                             1.12                                     \< 0.01
  Lung (Squamous cell carcinoma)                        J01   Antibacterials for systemic use                     2537/2401            17,597/30,244           1.62 (1.51--1.75)                             1.16                                     \< 0.01
  Pharynx (Squamous cell carcinoma)                     N03   Antiepileptics                                      134/3127             703/32,450              1.60 (1.32--1.95)                             1.01                                     0.05
  Lung (Squamous cell carcinoma)                        R05   Cough and cold preparations                         580/6456             3195/68,899             1.60 (1.45--1.76)                             1.12                                     \< 0.01
  Lung (Carcinoid)                                      J01   Antibacterials for systemic use                     275/175              1987/2320               1.59 (1.25--2.01)                             1.16                                     \< 0.01
  Lung (Small cell carcinoma)                           J01   Antibacterials for systemic use                     2038/1831            14,794/22,787           1.58 (1.46--1.72)                             1.16                                     \< 0.01
  Bladder (Adenocarcinoma)                              J01   Antibacterials for systemic use                     114/111              856/1371                1.54 (1.12--2.13)                             1.16                                     0.02
  Lung (Squamous cell carcinoma)                        M05   Drugs for treatment of bone diseases                230/8172             1400/83,177             1.53 (1.32--1.77)                             0.98                                     0.09
  Lung (Small cell carcinoma)                           N02   Analgesics                                          1538/4,055           9975/47,049             1.53 (1.42--1.64)                             1.06                                     \< 0.01
  Lung (Adenocarcinoma)                                 P01   Antiprotozoals                                      335/12,924           1928/132,006            1.49 (1.32--1.68)                             1.14                                     \< 0.01
  Corpus uteri (Adenocarcinoma, endometrioid)           C03   Diuretics                                           1438/3135            11,378/34,576           1.48 (1.38--1.59)                             1.05                                     \< 0.01
  Lung (Adenocarcinoma)                                 J01   Antibacterials for systemic use                     4541/3,529           35,295/44,294           1.48 (1.40--1.56)                             1.16                                     \< 0.01
  Larynx (Squamous cell carcinoma)                      R05   Cough and cold preparations                         131/2104             747/22,159              1.48 (1.21--1.80)                             1.12                                     \< 0.01
  Oesophagus (Squamous cell carcinoma)                  N05   Psycholeptics                                       410/1249             2936/13,955             1.47 (1.30--1.67)                             1.08                                     0.03
  Hodgkin (Other)                                       J01   Antibacterials for systemic use                     342/390              2679/4428               1.46 (1.20--1.78)                             1.16                                     \< 0.01
  Lung (Small cell carcinoma)                           N05   Psycholeptics                                       1752/4204            12,313/47,245           1.46 (1.37--1.55)                             1.08                                     \< 0.01
  Pharynx (Squamous cell carcinoma)                     N02   Analgesics                                          559/2255             3495/25,627             1.45 (1.30--1.62)                             1.06                                     0.03
  Lung (Squamous cell carcinoma)                        N02   Analgesics                                          1876/5158            12,176/60,203           1.45 (1.36--1.55)                             1.06                                     \< 0.01
  Corpus uteri (Adenocarcinoma, endometrioid)           C09   Agents acting on the renin--angiotensin system      1055/3824            8204/40,669             1.45 (1.34--1.56)                             1.01                                     \< 0.01
  Liver (Hepatocellular carcinoma)                      M01   Antiinflammatory and antirheumatic products         342/615              2393/7353               1.43 (1.22--1.69)                             1.04                                     0.04
  Lung (Other (non-small cell))                         J01   Antibacterials for systemic use                     1127/1070            8380/13,046             1.43 (1.29--1.59)                             1.16                                     \< 0.01
  Leukaemia (Lymphatic)                                 J01   Antibacterials for systemic use                     836/1025             7235/12,145             1.40 (1.24--1.57)                             1.16                                     0.04
  Leukaemia (Myeloid)                                   J01   Antibacterials for systemic use                     698/822              5684/9407               1.39 (1.22--1.59)                             1.16                                     \< 0.01
  Breast (female) (Adenocarcinoma, Ductal carcinoma)    G03   Sex hormones and modulators of the genital system   14,170/18,036        117,211/201,628         1.37 (1.34--1.40)                             1.12                                     \< 0.01
  Lung (Adenocarcinoma)                                 R05   Cough and cold preparations                         864/10,808           5863/114,283            1.36 (1.26--1.47)                             1.12                                     \< 0.01
  Lung (Squamous cell carcinoma)                        N05   Psycholeptics                                       2063/5489            15,025/60,826           1.36 (1.29--1.44)                             1.08                                     \< 0.01
  Lung (Other (non-small cell))                         N02   Analgesics                                          816/2388             5636/26,768             1.35 (1.22--1.48)                             1.06                                     \< 0.01
  Lung (Adenocarcinoma)                                 N05   Psycholeptics                                       3435/9225            25,688/100,862          1.34 (1.28--1.40)                             1.08                                     \< 0.01
  Lung (Other (non-small cell))                         N05   Psycholeptics                                       955/2406             7109/26,670             1.34 (1.23--1.46)                             1.08                                     \< 0.01
  Corpus uteri (Adenocarcinoma, endometrioid)           C07   Beta blocking agents                                781/4068             6331/42,068             1.32 (1.21--1.43)                             0.99                                     \< 0.01
  Lung (Adenocarcinoma)                                 N02   Analgesics                                          2951/8915            21,622/99,702           1.32 (1.25--1.38)                             1.06                                     \< 0.01

Notes: OR = odds ratio; CI = confidence interval.

*p*-Value as obtained in the dose--response analysis.

Adjusted for gender, age, and calendar time (by design) as well as Charlson Comorbidity Index (CCI) score and educational level.

Specificity, i.e. the association (OR) between the drug and overall cancer risk.
